She is not cured, but this surgery has clearly improved her quality of life.
For the millions living with advanced Parkinson's disease, the later stages have long meant a narrowing world — the loss of movement, of sleep, of ordinary life. Two new devices, emerging from separate research teams, now suggest that medicine may be learning to work around the disease's cruelest effects rather than waiting to reverse them. A spinal cord implant helped one patient walk where she once could only fall, and a nighttime pump restored sleep that tremors and depleted dopamine had long stolen. The findings are early and incomplete, but they point toward a different philosophy of care: not cure, but reclamation.
- Advanced Parkinson's disease strips patients of basic function — the ability to stand without fainting, to sleep through a night — confining millions to beds and wheelchairs with few options.
- A spinal cord implant designed to restore the brain's blood-pressure regulator allowed one patient to walk 250 meters, a distance that had been impossible just months before her surgery.
- A separate pump device delivering continuous dopamine replacement overnight significantly improved sleep quality in a randomized trial, sidestepping the spikes and crashes caused by traditional pill-based medication.
- Both treatments carry real limitations: the implant was tested on a single patient who did not technically have Parkinson's, and the pump trial enrolled fewer than fifty people — leaving major questions about broader efficacy unanswered.
- Researchers are cautiously optimistic, framing these not as cures but as a strategic pivot — finding ways to restore lost function through targeted intervention rather than waiting for a reversal of underlying neurological damage.
Advanced Parkinson's disease is a thief of small freedoms — the ability to cross a room, to sleep through the night. For millions worldwide, the later stages mean confinement to a bed or wheelchair, the body's geography shrinking year by year. Two new devices suggest some of what the disease takes might be recoverable.
The first targets orthostatic hypotension, a condition in which blood pressure collapses the moment a patient stands. In healthy people, the brain compensates automatically; in advanced Parkinson's, that regulator fails. A woman in her late forties would faint after just a few steps. Neurosurgeon Jocelyne Bloch and researcher Gregoire Courtine implanted a device into her spinal cord to stimulate that broken system. Three months later, she walked 250 meters with a walking frame. She is not cured, but the surgery, published in the New England Journal of Medicine, visibly changed the texture of her daily life. One important caveat: she had initially been misdiagnosed with Parkinson's, and whether the implant will work for confirmed patients remains an open question.
The second device addresses insomnia, which affects more than three-quarters of Parkinson's patients globally. The disease disrupts sleep through uncontrolled tremors and dopamine depletion — and the standard medication, apomorphine, creates its own problem when taken as a pill, spiking and crashing in ways that fragment sleep further. A team led by Emmanuel Flamand-Roze tested a small pump that delivers apomorphine continuously through the night. In a randomized trial published in Lancet Neurology, patients using the pump reported significantly better sleep than those on placebo. Wearing it in bed, the researchers noted, is far less burdensome than carrying one during the day.
Neither device is a cure. The implant study involved one patient; the pump trial fewer than fifty. But together they represent a meaningful shift in approach — not reversing Parkinson's underlying damage, which remains beyond reach, but finding clever ways around it. For people who have lost the ability to walk across a room or sleep through a night, that distinction matters enormously.
Advanced Parkinson's disease is a thief of small freedoms. It takes the ability to walk across a room. It steals sleep. For millions of people worldwide living with this degenerative condition, the later stages mean confinement—to a bed, to a wheelchair, to the narrowing geography of what a body can still do. But two new devices, emerging from research labs in recent weeks, suggest that some of these losses might be recoverable.
The first obstacle is orthostatic hypotension, a condition where blood pressure plummets the moment a person stands. In healthy people, the brain has a regulator that senses this shift and compensates, ensuring blood keeps flowing upward. In advanced Parkinson's patients, this regulator fails. A few steps forward and the world tilts. Dizziness comes. Then darkness. A woman in her late forties experienced this acutely—she would collapse after barely moving. Neurosurgeon Jocelyne Bloch and researcher Gregoire Courtine, working in France, implanted a device into her spinal cord designed to stimulate that broken regulator, essentially reminding her brain to do what it had forgotten.
Three months after surgery, she walked 250 meters with a walking frame. Before the implant, she couldn't manage a handful of steps without fainting. The woman is not cured. She will not run marathons. But the surgery, as Bloch noted to the press, clearly changed the texture of her daily life. The research appeared in the New England Journal of Medicine, though it bears noting that this was a single case—a proof of concept rather than a proven treatment. The woman did not technically have Parkinson's, though her symptoms were similar enough that she had initially been misdiagnosed with it. Whether the implant will work the same way for actual Parkinson's patients remains an open question that requires further study.
The second problem is insomnia, which haunts more than three-quarters of the roughly ten million people with Parkinson's globally. The disease disrupts sleep in two ways: the uncontrolled tremors that jolt patients awake, and the depletion of dopamine, the neurotransmitter that regulates both movement and sleep. Doctors have long used a medication called apomorphine to replace missing dopamine, but when taken as a pill, it creates a problem of its own—the drug spikes and then crashes, triggering muscle spasms that further fragment sleep.
A team led by Emmanuel Flamand-Roze tested a different delivery method: a small pump, resembling an insulin pump, that dispenses apomorphine continuously throughout the night. In a randomized trial published in Lancet Neurology, patients using the pump reported significantly better sleep than those receiving a placebo. The device's advantage is practical as well as medical. Wearing a pump at night, Flamand-Roze explained, is far less burdensome than carrying one during waking hours. You are in bed anyway. The constraint becomes almost invisible.
Both treatments remain early-stage. The spinal implant study involved one patient. The pump study, while larger, still enrolled fewer than fifty people and focused on those already in advanced disease stages. Neither device is a cure. Neither restores what Parkinson's has taken. But they represent a shift in how medicine approaches the disease's cruelest symptoms—not by trying to reverse the underlying neurological damage, which remains intractable, but by finding ways to work around it, to restore function through clever intervention. For people who have lost the ability to walk across a room or sleep through a night, that distinction matters enormously. The research is preliminary, but the direction is clear: some of what Parkinson's steals might yet be given back.
Citas Notables
She is not cured, she would not run a marathon, but this surgery has clearly improved her quality of life.— Neurosurgeon Jocelyne Bloch, describing the implant patient's outcome
The constraints linked to wearing a small pump are much lower during the night, compared to carrying such a device around all day.— Emmanuel Flamand-Roze, on the practical advantages of the apomorphine pump
La Conversación del Hearth Otra perspectiva de la historia
Why does Parkinson's specifically attack the ability to walk and sleep? Are those just the most noticeable symptoms, or is there something about how the disease works that targets those functions?
It's both. The disease erodes dopamine-producing neurons throughout the brain, but the systems that control movement and sleep are particularly sensitive to that loss. Walking requires a coordinated chain of signals from brain to muscle—when dopamine drops, that chain breaks. Sleep is similar; dopamine helps regulate the sleep-wake cycle. But there's also the orthostatic hypotension piece, which is almost a secondary injury. The brain's blood pressure regulator gets disrupted, so even if a patient wanted to stand, their body won't cooperate.
The spinal implant is fascinating, but it seems to work differently for paralyzed people than for Parkinson's patients. Can you explain that distinction?
Right. For someone with a severed spinal cord, the implant essentially bridges the gap—it sends electrical signals that the brain can no longer reach. For Parkinson's, the spinal cord is intact. The implant instead targets a specific regulator in the brain itself, the one that's supposed to sense when you stand and compensate. It's stimulating a broken switch rather than rewiring a broken circuit.
And the pump—why is continuous delivery so much better than taking a pill?
Because pills create peaks and valleys. You take apomorphine, it floods your system, your muscles spasm, then it wears off and you're back where you started. A pump delivers a steady, low dose all night. No spikes, no crashes. Your body gets what it needs without the violent swings that keep you awake.
Both studies seem small. Why should anyone be hopeful?
Because they work at all. These aren't theoretical. A woman who couldn't walk twenty steps now walks 250 meters. Patients on the pump sleep better. The sample sizes are small, yes, but the effect sizes are real. The next phase is scaling up, testing on actual Parkinson's populations, refining the approach. That's how medicine moves forward—proof of concept first, then validation.
What happens to the people in these studies after the research ends?
The woman with the implant keeps it. The pump users keep their devices if they want them. These aren't temporary experiments. If the treatment works, it stays. That's the real test—whether people choose to keep using these things in their actual lives, not in a controlled study.